Alkermes Reports Phase 2 Vibrance‑2 Data; Says Alixorexton Trial In Narcolepsy Type 2 Meets Dual Primary Endpoints, Showing Sustained Wakefulness Gains

뉴스 본문을 불러오고 있어요.

Alkermes Reports Phase 2 Vibrance‑2 Data; Says Alixorexton Trial In Narcolepsy Type 2 Meets Dual Primary Endpoints, Showing Sustained Wakefulness Gains | 웨이프 WAPE

Alkermes Reports Phase 2 Vibrance‑2 Data; Says Alixorexton Trial In Narcolepsy Type 2 Meets Dual Primary Endpoints, Showing Sustained Wakefulness Gains

기사 요약

관련 종목

댓글 —